Examination of the effectiveness against retinal vascular occlusion treated with retinal endovascular surgery using tissue plasminogen activator.

Examination of the effectiveness against retinal vascular occlusion treated with retinal endovascular surgery using tissue plasminogen activator. - Examination of retinal endovascular surgery against retinal vascular occlusion.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024593

Enrollment

Registered

2017-01-01

Start date

2017-01-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

retinal vein occlusion retinal artery occlusion

Interventions

We inject tissue plasminogen activator (t-PA, a monteplase) 5000IU into a retinal vascular used in vitreous surgery.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patient undergoing vitreous surgery and stay in hospital for about one week in our hospital. The patient receives a sufficient explanation about vitreous surgery. The patient who we can get a patient's informed consent before conducting the treatment.

Exclusion criteria

Exclusion criteria: We take patient's past medical history. We exclude a patient with cerebrovascular disorders and patient with a history of cerebral infarction and blood disease. And the case is judged to be at high risk to use t-PA for patients.

Design outcomes

Primary

Measure	Time frame
Postoperative week 1 : visual acuity, postoperative complication , Optical Coherence Tomography (OCT) Postoperative week 4 : visual acuity, postoperative complication , OCT Postoperative week 12 : visual acuity, postoperative complication , OCT Postoperative week 24 : visual acuity, postoperative complication , OCT , fluorescein fundus angiography (FAG)	—

Countries

Japan

Contacts

Public ContactYoichiro Shinkai

Kyoto Prefectual Univercity of Medicine Department of Ophthalmology

yshinkai@koto.kpu-m.ac.jp075-251-5578

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026